Cost-effectiveness of Chronic Hepatitis C Treatment with Thymosin Alpha-1

Archives of Medical Research

Volumn 37, Issue 5, 2006, Pages 663-673

  García Contreras, Fernando ^a   Nevárez Sida, Armando ^a   Constantino Casas, Patricia ^a   Abud Bastida, Fernando ^a   Garduño Espinosa, Juan ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Chronic hepatitis C; Cost effectiveness; Economic evaluation; Peginterferon; Ribavirin; Thymosin alpha 1

Indexed keywords

PEGINTERFERON; RIBAVIRIN; THYMOSIN ALPHA1;

ARTICLE; COST EFFECTIVENESS ANALYSIS; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; PROBABILITY; QUALITY OF LIFE; SENSITIVITY ANALYSIS;

ADJUVANTS, IMMUNOLOGIC; ANTIVIRAL AGENTS; COSTS AND COST ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LIVER CIRRHOSIS; MALE; MEXICO; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RIBAVIRIN; THYMOSIN;

EID: 33646857512     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2005.11.010     Document Type: Article

References (34)

1. http://www.who.int/mediacentre/factsheets/fs164/en/ (accessed September 2004).
2. th year. http://www.who.int/wer (accessed September 2004).
3. Liaw Y.F. Current therapeutic trends in therapy for chronic viral hepatitis. J Gastroenterol Hepatol 12 suppl (1997) S346-S353
4. Hoofnagle J.H., and Di Bisceglie A.M. The treatment of chronic viral hepatitis. N Engl J Med 226 (1997) 347-356
5. Christian T., Fabien Z., and Pierre P. Viral hepatitis. Curr Opin Infect Dis 12 (1999) 481-490
6. Chemello L., Cavalletto L., Casarin C., Bonetti P., Bernardinello E., Pontisso P., et al. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-α in chronic hepatitis C. Ann Intern Med 124 (1996) 1058-1060
7. Reichard O., Andersson J., Schvarcz R., and Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet 337 (1991) 1058-1061
8. Thomas H.C., Torok M.E., Forton D.M., and Taylor-Robinson S.D. Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C. J Hepatol 31 suppl 1 (1999) 152-159
9. Dusheiko G., Main J., Thomas H., Reichard O., Lee C., Dhillon A., et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 25 (1996) 591-598
10. Di Bisceglie A.M., Conjeevaram H.S., Fried M.W., Sallie R., Park Y., Yurdaydin C., et al. Rivabirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 123 (1995) 897-903
11. Brillanti S., Garson J., Foli M., Whitby K., Deaville R., Masci C., et al. A pilot study of combination therapy with ribarivin plus interferon alpha for interferon alpha-resistant chronic hepatitis C. Gastroenterology 107 (1994) 812-817
12. Lai M.Y., Kao J.H., Yang P.M., Wang J.T., Chen P.J., Chan K.W., et al. Long-term efficacy of ribavirin plus interferon alpha in the treatment of chronic hepatitis C. Gastroenterology 11I (1996) 1307-1312
13. Reichard O., Norkrans G., Fryden A., Braconier J.H., Sonnerborg A., Weiland O., and for the Swedish Study Group. Randomised, double-blind, placebo-controlled trial of interferon (alpha2b) with and without ribavirin for chronic hepatitis C. Lancet 351 (1998) 83-87
14. Poynard T., Marcellin P., Lee S.S., Niederau C., Minuk G.S., Ideo G., et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352 (1998) 1426-1432
15. Younossi Z.M., Mendel E.S., McHutchison J.G., and Shermock K.M. Cost effectiveness of interferon α2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 30 (1999) 1318-1324
16. McHutchison J.G., and Hoofnagle J.H. Therapy of chronic hepatitis C. In: Liang T.J., and Hoofnagle J.H. (Eds). Hepatitis C: Biomedical Research Reports (2000), Academic Press, New York 203-239
17. Ancell C., Phipps J., and Young L. Thymosin alpha-1. Am J Health System Pharmacy 58 (2001) 879-888
18. Wong J.B., McQuillan G.M., McHutchison J.G., and Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the US. Am J Public Health 90 (2000) 1562-1569
19. Siebert U., Sroczynski G., Rossol S., Waseon J., Ravens-Sieberer U., Kurth B., et al. Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 52 (2003) 425-432
20. Buti M, Casado MA, Fosbrook L, Wong JB, Esteban R. Cost-effectiveness of combination therapy for naïve patients with chronic hepatitis C. J Hepatol 200;33:651-658.
21. Pawlotsky J.M. Current and future concepts in hepatitis C Therapy. Semin Liver Dis HCV New Paradigms 25 (2005) 72-83
22. Mangia A., Ricci G., Persico M., Minerva N., Carretta V., Bacca D., et al. A randomized control trial of pegylated interferon (alpha)-2a (40 KD) or interferon (alpha)-2a plus ribavirin and amantadine vs interferon (alpha)-2a and ribavirin in treatment-naive patients with chronic hepatitis C. J Viral Hepatitis 12 (2005) 292-299
23. Keating G.M., and Plosker G.L. Peginterferon (alpha)-2a (40 KD) plus ribavirin: a review of its use in the management of patients with chronic hepatitis C and persistently "normal" ALT levels. Drug 65 (2005) 521-536
24. Informe de la Dirección General. XCIV Asamblea General Ordinaria (2004), Agosto, México
25. nd ed. (2000), Oxford University Press, New York
26. Góngora J., Poo J.L., Sánchez-Avila F., Kershenobich D., García-Samper X., García-Sandoval M., et al. Eficacia y seguridad de la timosina alfa1, peginterferón alfa 2a y ribavirina en pacientes con hepatitis crónica por virus C no respondedores a tratamiento previo: resultados a 72 semanas. Medica Sur 12 (2005) 81-82
27. Yano M., Kumada H., Kage M., Ikeda K., Shimamatsu K., Inoue O., Hashimoto E., et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 23 (1996) 1334-1340
28. Fattovich G., Guistina G., and Degas F. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow up study of 384 patients. Gastroenterology 112 (1997) 463-472
29. Colombo M., de Franchis R., Del Ninno E., Sangiovanni A., De Fazio C., Tommasini M., et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 325 (1991) 675-680
30. Ascher N.L., Lake J.R., Emond J., and Roberts J. Liver transplantation for hepatitis C virus-related cirrhosis. Hepatology 20 (1994) 24S-27S
31. Thymalfasin package insert (1998), SciClone Pharmaceuticals International, San Mateo, CA
32. Sherman K.E., Sjogren M., Creager R.L., Damiano M., Freeman S., Lewey S., et al. Combination therapy with thymosin [alpha]1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. Hepatology 27 (1998) 1128-1135
33. Stein K., Rosenberg W., and Wong J. Cost effectiveness of combination therapy for hepatitis C: a decision analytic model. Gut 50 (2002) 253-258
34. Mendel E.S., and Zobair M.Y. Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. Am J Med 111 (2001) 614-621